AVBP Q4 2023 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$23M

Net Income

-$21M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$319,000

Balance Sheet

Total Assets

$163M

Total Liabilities

$12M

Stockholders' Equity

$151M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$23M	-$10M	-121.4%
Net Income	-$21M	-$10M	-103.0%